At the Intersection of Science and Law

Revolutionizing Clinical Trials: A discussion on diversity and patient-centric approaches

In this episode, Quest Diagnostics’ Adam Donat is joined by DLA Piper’s Kirsten Axelsen, Rachel Portman, and Jae Kim to discuss the increasing complexity and cost of clin

Life sciences companies and the risks posed by the mifepristone litigation

In this episode, a cross-disciplinary team of FDA regulatory lawyers and life sciences litigators discuss the implications of the mifepristone litigation for life science

Trade secrets protection in the life sciences sector

DLA Piper’s Roberto Valenti and Ray Miller discuss trade secrets protection in the US and Europe and the peculiarities within the life sciences sector. Our speakers provi

Cross-border considerations for privacy in clinical trials

Published in Chambers Expert Focus. With the recent publication of our Cross-border Guide to Clinical Trials and Privacy, James Clark, Paula Gonzalez de Castejón and Davi

Global Life Sciences Supply Chain Insights

Published in Chambers Expert Focus. Lauren Murdza and Richard Taylor share their insights on supply chain issues in the life sciences sector in the latest episode of At t

AI risk assessments: Future-proofing your innovation when rules can change mid-game

Published in Chambers Expert Focus. DLA Piper partner Danny Tobey is joined by Aviva Wein, Assistant General Counsel at Johnson & Johnson, to discuss how medical device a

The rise of global telehealth

DLA Piper partners Kristi Kung and Greg Bodulovic discuss the rise of telehealth amid the COVID-19 pandemic, as well as advancements in technology aiming to address dispa

Advising the advisor: Tips for navigating the life sciences and regulatory environment

DLA Piper managing partner Emilio Ragosa is joined by Kevin Sheridan, Joint Global Head of Healthcare Investment Banking at Jefferies LLC, to discuss the importance of ad

The moral imperative: Balancing innovation, regulation and prescription drug availability

DLA Piper's Jim Greenwood and Geoff Levitt are joined by Peter Kolchinsky, founding Partner and Portfolio Manager at RA Capital, to discuss the importance of – and compli

Incentivizing diverse representation in clinical trials

Diverse representation in clinical trials is critical in achieving greater equity and better healthcare outcomes. DLA Piper's Kirsten Axelsen and Sarah Schick are joined

The crossroad of science and law

DLA Piper’s Lucas Przymusinski and Raymond Williams are joined by Michael King, Vice President and Associate General Counsel at Jazz Pharmaceuticals, to discuss the benef

Social media’s impact on the life sciences industry

DLA Piper’s Chris Campbell and Jody Rhodes are joined by Sarah Heineman, Senior Assistant General Counsel at Bayer, to discuss how social media affects the public's view

Understanding AI and its use in drug discovery

DLA Piper partners Ellen Scordino and Susan Krumplitsch are joined by Duane Valz, General Counsel of Insitro, to discuss how machine learning is being used to generate an

mRNA technology and the COVID-19 vaccine: A conversation with Pfizer’s Kathy Fernando

For decades, scientists have studied the seemingly endless possibilities of custom-made messenger RNA, or mRNA. Kathy Fernando, Head Vice President, Worldwide of Clinical